CBO report on AHCA impact coming later in May

The Congressional Budget Office (CBO) will release an updated report on how the American Health Care Act (AHCA) could affect insurance coverage and federal healthcare spending, with the score expected to be released the week of May 22.

The Republican-sponsored replacement plan for the Affordable Care Act (ACA) passed the House by a narrow margin on May 4. The CBO had issued two reports on earlier versions of the legislation, estimating it would lead to 24 million more people becoming uninsured by 2026. The version which was approved by the House, however, has not been scored by the CBO.

White House spokesman Sarah Huckabee Sanders had defended pushing the bill through the House without a CBO report—which had been completed before a vote on the ACA—arguing its state waiver provisions made such an examination too complicated.

“I think even if they were to score it it’s impossible to score a lot of the things that would go into this because it has so many different factors that you simply can’t predict what governors may do in their states, specific conditions that patients may have,” Sanders said in a May 4 press briefing. “So even if it was to be scored, I think it would be impossible to predict how that might actually affect and impact.”

Senate rules require a CBO score before any vote takes place since the legislation is moving through the budget reconciliation process.

Democratic leaders have predicted the new report will be more damaging to the AHCA than those completed in March.

“When the CBO (report) comes out on this, it’s going to be even worse,” said House Minority Leader Nancy Pelosi, D-California, after the House bill was passed.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup